Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit. While essential thrombocythemia (ET) is classified as ...

National Comprehensive Cancer Network publishes new guidelines for Pediatric Soft Tissue Sarcomas, focused on rhabdomyosarcoma. PLYMOUTH MEETING, Pa., Feb. 17, 2026 /PRNewswire/ -- The National ...

The NCCN has updated its guidelines on breast, pancreatic, colon, rectal, non-small cell lung, and other cancers. The National Comprehensive Cancer Network (NCCN) has updated its treatment guidelines ...

Medscape Hematology-Oncology is pleased to present the latest update to the NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, released in December 2009. The updated NCCN Guideline, ...

PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...

The National Comprehensive Cancer Network ® (NCCN ®) - an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven guidelines for care - announces the ...

Dr. Gerd examines the clinical choices involved in the management of PV, following the directives of NCCN guidelines. Aaron Gerds, MD, MS: The NCCN [National Comprehensive Cancer Network] guidelines ...

FDA approved concept. Rubber stamp with FDA and medicine. 3d illustration Cancer drugs that are granted accelerated approval are less likely than drugs with regular approval to be given high-level ...

HOLLYWOOD, Florida ― Now in their 20th year, the National Comprehensive Cancer Network (NCCN) guidelines have greatly evolved from early efforts and continue to add new wrinkles, according to ...

Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix.NCCN Cutaneous Melanoma Guidelines ...

Panelists discuss how payer coverage restrictions often conflict with NCCN guidelines for BTK inhibitor therapies in CLL, impeding evidence-based care. Panelists discuss how payer coverage often ...